Rikke Løvendahl Eefsen

13PUBLICATIONS
156CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsRadiation therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Oct 15, 2026
Anti-TNFR2 antibody BI-1808 induces tumor regression and antitumor T cell immunity through T reg and myeloid cell modulation in patients with solid tumors.

|Jul 23, 2026
Randomized phase II trial of nivolumab and ipilimumab with or without stereotactic body radiation therapy in patients with metastatic castration-resistant prostate cancer: the CheckPRO, CA209-8TY trial.

|May 13, 2026
Early ctDNA Dynamics Predict Response to Mosperafenib in BRAF V600-Mutant Metastatic Colorectal Cancer.

|May 11, 2026
Real-world outcomes of pembrolizumab in advanced anal cancer: a nationwide Danish anal Cancer Group report.

|Mar 27, 2026
Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With BRAF V600-Mutant Solid Tumors.

Maria Vieito, Elisa Fontana, Catherine H Han

|Nov 18, 2025
Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen-Positive Advanced/Metastatic Solid Tumors.

Ignacio Melero, Josep Tabernero, Neeltje Steeghs

Pageof 3

Frequent Collaborators

3 joint publications

Dorte Lisbeth Nielsen

2 joint publications

David Dejardin

2 joint publications

Eduardo Castañón Álvarez

2 joint publications

Elisa Fontana